Company news

Share this article:
Lilly will pay $62 million to 32 states investigating the company over its marketing of Zyprexa, an antipsychotic drug indicated for schizophrenia and some forms of bipolar disorder. Eleven other states – and the federal government – will continue to investigate Zyprexa promotions, and may cost the company more money in the future. The company is accused of marketing the drug off-label, for dementia and milder forms of bipolar disorder that have not been approved by FDA.

AtheroGenics, an Alpharetta, GA–based pharmaceutical company, filed for Chapter 11 bankruptcy on September 15 in the US Bankruptcy Court for the Northern District of Georgia in Atlanta, due to a substantial debt burden. AtheroGenics expects to sell the company and/or its key assets. AtheroGenics focused on the treatment of chronic inflammatory diseases including diabetes and coronary heart disease.   
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.